FAU Researchers Confront New U.S. and Global Challenges in Vaccinations of Adults

Over the past decade, decreasing vaccination rates now threaten the huge beneficial impacts of vaccinations in the U.S. and globally. Researchers discuss the multifactorial barriers including increasing vaccine hesitancy and new clinical and public health challenges in vaccinations of U.S. adults.

Researchers Endorse Widespread Naloxone Over the Counter to Prevent Drug Overdose Deaths

Naloxone is an opioid receptor antagonist that rapidly reverses or blocks the effects of opioids, restores normal respiration and heart rhythm, and reverses the potentially fatal effects of an overdose. Although naloxone is included in U.S. CDC recommendations, the drug is currently prescribed to less than 1 in 70 patients prescribed high-dose opioid prescriptions. Researchers propose a call to action for all health providers and state medical societies to ensure the widest distribution and easy availability of naloxone, including over the counter, which is likely to be FDA-approved very soon.

Rutgers Launches Genetic Testing Service for New Coronavirus

Rutgers’ RUCDR Infinite Biologics has launched a test for the SARS-CoV-2 coronavirus and is using its automation experience and infrastructure to test as many as tens of thousands of samples daily. RUCDR has also submitted an emergency use authorization request for a saliva collection method that will allow for broader population screening.

Researchers Challenge New Guidelines on Aspirin in Primary Prevention

New guidelines recommend aspirin use in primary prevention for people ages 40 to 70 years old who are at higher risk of a first cardiovascular event, but not for those over 70. Yet, people over 70 are at higher risks of cardiovascular events than those under 70. As a result, health care providers are understandably confused about whether or not to prescribe aspirin for primary prevention of heart attacks or strokes, and if so, to whom.